Car T-Cell Therapy
CAR-T ‘definitively’ superior as second-line therapy for large B-cell lymphoma
CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.
FDA grants fast-track designation to second CAR T-cell therapy for lupus nephritis
The FDA has granted fast-track designation to Kyverna’s KYV-101, a novel anti-CD19 chimeric antigen receptor T-cell therapy for patients with refractory lupus nephritis, according to a company press release.
VIDEO: Awareness of cell therapy, ‘novel therapeutics’ in DLBCL benefits patients, providers
In a video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses who benefits from awareness surrounding DLBCL.
CAR-T cell therapy, recent approvals put precision medicine ‘on the horizon’ for lupus
The recent success of chimeric antigen receptor-T cell therapy, along with three high-profile FDA approvals, may help make precision medicine a reality in lupus, according to a presenter at the Biologic Therapies Summit.
Novel leukemia treatment signals ‘new era in CAR T-cell therapy’
An investigational chimeric antigen receptor T-cell therapy demonstrated successful expansion and antitumor targeting among younger patients with advanced acute myeloid leukemia, results of the phase 1 PLAT-08 trial showed.
FDA clears way for CAR T-cell therapy trial in patients with myositis
The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with myositis, according to a press release from the manufacturer.
Researchers use CAR T-cell therapy to pursue new prostate cancer target
An immunotherapy regimen featuring a novel chimeric antigen receptor T-cell therapy demonstrated antitumor activity against metastatic prostate cancer models, study results published in Nature Communications showed.
B-cell system reset in CAR T-cell therapy ‘feasible,’ leads to durable remission in lupus
In patients with systemic lupus erythematous, CAR T-cell therapy appears to be a feasible and effective method of achieving durable remission, according to a speaker at the Biologic Therapies Summit.
Breyanzi CAR-T trials meet primary endpoints for follicular, mantle cell lymphomas
Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer.
Bispecific CAR-T induces durable responses in advanced non-Hodgkin lymphoma
Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results.